takedaventures.com
Takeda Ventures, Inc. > TVI Portfolio
http://www.takedaventures.com/portfolio
Skip to main content. ArmaGen, Inc (CA, USA). Has developed a receptor transcytosis Trojan Horse technology platform enabling non-invasive delivery of biotherapeutics across the blood-brain barrier. The company is initially focusing on treatment of lysosomal storage diseases, where CNS involvement cannot be addressed by current standards of care. CellCentric, Ltd. (Cambridge, UK). Domainex, Ltd (Cambridge, UK). Encycle Therapeutics, Inc. (ON, Canada). Is pioneering the development of nacellins, small cyc...
boehringer-ingelheim-venture.com
Portfolio
http://www.boehringer-ingelheim-venture.com/portfolio.html
Boehringer Ingelheim Venture Fund 07 July 2016. Jump to main navigation. The Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs. Year of investment: 2011; BIVF Board Representative: Martin Heidecker. Year of investment: 2011; BIVF Board Representative: Frank Kalkbrenner. Promethera Biosciences S.A./N.V. Year of investment: 2012; BIVF Board Representative: Ilka Wicke.